An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

Abstract Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral...

Full description

Bibliographic Details
Main Authors: Alexander D. James, Hilmar Schiller, Cyrille Marvalin, Yi Jin, Hubert Borell, Ad F. Roffel, Ulrike Glaenzel, Yan Ji, Gian Camenisch
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Pharmacology Research & Perspectives
Subjects:
ADME
human
Kisquali
preclinical
Ribociclib
Online Access:https://doi.org/10.1002/prp2.599

Internet

https://doi.org/10.1002/prp2.599

Similar Items